For example, though non‐small‐cell lung cancer (NSCLC) patients carrying activating mutations in EGFR (epidermal growth factor receptor) initially respond to EGFR‐targeted tyrosine kinase inhibitors (EGFR‐TKIs; Lynch et al, 2004; Paez et al, 2004), the emergence of mutations that confer resistance to these TKIs or activate alternative drivers (such as EGFR T790M, MET/HER2 amplifications, PIK3CA mutation) leads to eventual drug resistance (Yu et al, 2013; Camidge et al, 2014). Here, EGFR is linked to non-small cell lung carcinoma.